Two Seas Capital LP bought a new position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 14,835,146 shares of the biotechnology company's stock, valued at approximately $7,992,000. Adaptimmune Therapeutics comprises approximately 0.7% of Two Seas Capital LP's portfolio, making the stock its 20th biggest position. Two Seas Capital LP owned approximately 5.80% of Adaptimmune Therapeutics at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in the business. Invesco Ltd. grew its position in shares of Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after buying an additional 28,526 shares during the period. Virtu Financial LLC boosted its position in Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after acquiring an additional 21,688 shares during the last quarter. LPL Financial LLC grew its stake in shares of Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 94,623 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after acquiring an additional 98,581 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its position in shares of Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 58,000 shares in the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.
Adaptimmune Therapeutics Stock Performance
Shares of NASDAQ:ADAP traded down $0.00 during trading on Friday, reaching $0.27. 469,528 shares of the stock were exchanged, compared to its average volume of 1,766,401. The firm has a market cap of $68.24 million, a PE ratio of -1.21 and a beta of 2.84. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics plc has a 12 month low of $0.20 and a 12 month high of $1.48. The stock has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.55.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The company had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. Research analysts expect that Adaptimmune Therapeutics plc will post -0.14 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on ADAP shares. Scotiabank cut their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research report on Friday, March 21st. HC Wainwright cut their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim lowered their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research note on Wednesday, March 26th. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday, March 21st. Finally, StockNews.com initiated coverage on Adaptimmune Therapeutics in a research report on Tuesday, April 22nd. They set a "buy" rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1.83.
View Our Latest Stock Report on ADAP
About Adaptimmune Therapeutics
(
Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
